Disease
Epilepsy
Chronic neurological disorder of recurrent unprovoked seizures, spanning focal and generalised syndromes; roughly a third of patients are drug-resistant.
Coverage in progress. AssetMemo has not yet run its full census for Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures, Dravet Syndrome and Developmental Epileptic Encephalopathies, Absence Seizures, so the assets listed for them are not complete.
Combined attributable cost
$40.8B+
Drug spend
$18.4B+
45% of total cost is drugs
Sum of 5 indications below.
Indications
Epilepsy
$40.8B attributable cost
$5,417/patient drugs
All severities (active epilepsy) · US
Focal Onset Seizures
Market size not yet sourced
All-stage · US
Primary Generalized Tonic-Clonic Seizures
Market size not yet sourced
All-stage · US
Dravet Syndrome and Developmental Epileptic Encephalopathies
Market size not yet sourced
All-stage · US
Absence Seizures
Market size not yet sourced
All-stage · US